Sernova Announces New Positive Data from Phase I/II Trial Regarding Islet Survival and Function
September 12, 2024 08:00 ET
|
Sernova Corp.
Abundant, richly vascularized and functioning islets observed throughout all chambers of Sernova’s Cell Pouch more than 5 years after islet transplantationHistological data confirmation of healthy...
Sernova Corp. Announces Appointment of New Chief Executive Officer
August 12, 2024 07:45 ET
|
Sernova Corp.
LONDON, Ontario and BOSTON, Aug. 12, 2024 (GLOBE NEWSWIRE) -- August 12, 2024. Sernova Corp. (“Sernova” or the “Company”) (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage biotechnology...
Sernova Receives Orphan Drug and Rare Pediatric Disease Designations for its Hemophilia A Program from FDA
November 27, 2023 07:19 ET
|
Sernova Corp.
LONDON, Ontario and WINDHAM COUNTY, Conn., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today...
Sernova Announces New Advancements of Conformal Coating Technology in Combination with the Cell Pouch System™ at the 2023 IPITA-IXA-CTRMS Joint Congress
October 30, 2023 07:00 ET
|
Sernova Corp.
LONDON, Ontario and WINDHAM COUNTY, Conn., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today...
Sernova Announces Positive Ongoing Interim Phase 1/2 Clinical Data for the Cell Pouch System™ for Type 1 Diabetes Trial at the 2023 IPITA, IXA, and CTRMS Joint Congress
October 27, 2023 07:00 ET
|
Sernova Corp.
All six patients in the first cohort (Cohort A) were successfully implanted with the 8-channel Cell Pouch System with post-transplant follow-up periods ranging from 6 months to 3.5 years;5 of 6...
Sernova to Provide Two Program Updates in Podium Presentations at 2023 IPITA Congress
October 11, 2023 07:00 ET
|
Sernova Corp.
Dr. Piotr Witkowski presenting new data from ongoing Phase 1/2 clinical trial of the Cell Pouch System™ in patients with type 1 diabetes (T1D) Dr. Alice Tomei presenting preclinical data on...
Sernova Presents Compelling New Data on the Cell Pouch System™ as a Promising Treatment for Post-Operative Hypothyroidism at the 2023 American Thyroid Association Annual Meeting
September 29, 2023 09:50 ET
|
Sernova Corp.
LONDON, Ontario and WINDHAM COUNTY, Conn., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today...
Sernova Investor Conference Call Previously Scheduled for September 15 Now Rescheduled for September 22
September 14, 2023 16:05 ET
|
Sernova Corp.
LONDON, Ontario and WINDHAM COUNTY, Conn., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today...
Sernova to Host Investor Calls to Introduce Newly Appointed CEO and Provide Business Update
September 13, 2023 07:00 ET
|
Sernova Corp.
- Introduction of New CEO Cynthia Pussinen and Recently Appointed Chief Business Officer, Dr. Modestus Obochi, on September 15, 2023 - - Business Update, Strategy & Outlook Call on October 5,...
Sernova Provides Development Update on Proprietary Cellular Conformal Coating Technology in Combination with Cell Pouch Device
September 07, 2023 07:00 ET
|
Sernova Corp.
LONDON, Ontario and WINDHAM COUNTY, Conn., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today...